Research Article

Effects of Metoprolol Succinate Combined with Entresto on Cardiac Function Indexes and Coagulation Function in Patients with Congestive Heart Failure

Yuanyuan Ding,1 Zufa Wei,1 Jian Li,1 and Ling Zhu2

1Hubei Province Huangshi Puren Hospital Cardiovascular Medicine, 435002, China
2Audit Office of Huangshi Central Hospital, Hubei Province, China

Correspondence should be addressed to Ling Zhu; 846174469@qq.com

Received 20 February 2022; Revised 11 April 2022; Accepted 19 April 2022; Published 21 May 2022

Academic Editor: Min Tang

Copyright © 2022 Yuanyuan Ding et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. To investigate the effects of metoprolol succinate combined with Entresto (Sacubitril Valsartan Sodium Tablets) on cardiac function and coagulation function in patients with congestive heart failure (CHF).

Methods. About 120 patients with CHF treated from April 2018 to April 2021 were enrolled in our hospital. The patients were arbitrarily assigned into control group and study group. The control group was cured with metoprolol succinate sustained-release tablets, and the study group was cured with metoprolol succinate sustained-release tablets combined with Entresto. The curative effect, cardiac function, vascular endothelial function, oxidative stress, and coagulation function were compared.

Results. First of all, we compared the general data, and there exhibited no difference in age, sex, course of disease, hypertension, coronary heart disease, diabetes, atrial fibrillation, and other general data (P > 0.05). Second, we compared the clinical efficacy. The effective rate of the study group (98.33%) was higher (90.00%) (P < 0.05). There exhibited no significant difference in cardiac function indexes before treatment, but after treatment, LVEF increased, LVESD and LVEDD decreased, LVESD and LVEDD in the study group were lower, and LVEF in the study group was higher (P < 0.05). Before treatment, there exhibited no significant difference in vascular endothelial function. However, the levels of CGRP and ET increased and the level of NO decreased, and the level of NO in the study group was lower, while the levels of CGRP and ET in the study group were higher after treatment (P < 0.05). There exhibited no significant difference in oxidative stress indexes before treatment, however, the levels of GSH-Px and SOD increased and the levels of MDA decreased after treatment, while the level of MDA in the study group was lower, while the levels of GSH-Px and SOD in the study group were higher (P < 0.05). Finally, we compared the indexes of blood coagulation function. There exhibited no significant difference before treatment, but after treatment, the levels of APTT, PT, and FIB decreased, and the levels of APTT, PT, and FIB in the study group were lower (P < 0.05). Conclusion. Clinical practice demonstrated that LVESD and LVEDD decreased and LVEF increased after treatment with Entresto combined with metoprolol in CHF patients, which can effectively facilitate cardiac function and vascular endothelial function, reduce oxidative stress reaction, and improve blood coagulation indexes, suggesting that Entresto combined with metoprolol can improve ventricular remodeling with good safety.

1. Introduction

In recent years, cardiovascular disease has become one of the most serious diseases affecting human survival. Heart failure, as the end-stage manifestation of a variety of cardiovascular diseases, occupies a very important position in cardiovascular diseases [1]. Congestive heart failure (CHF) is a syndrome in which cardiac structure or function is abnormal for various reasons, resulting in impaired ventricular filling and ejection function, resulting in cardiac output that is difficult to meet the metabolic needs of the body, and resulting in a series of complex clinical manifestations [1]. At present, the total population of CHF is large worldwide. According to the epidemiological survey, the prevalence rate of CHF in
developed countries is 1-2%, and the prevalence rate of heart failure in adults aged 35-74 in China is 0.9% [2]. A previous epidemiological study on hospitalized patients in Hong Kong indicated that the total incidence of CHF was 0.7 ppm 1000 [1–3]. In recent years, the average life expectancy has also been extended, and the problem of aging has become increasingly prominent. For example, the incidence and comorbidity of various chronic diseases such as coronary heart disease (CHD), hyperlipidemia, diabetes, and chronic kidney disease are significantly increased [4]. These diseases may directly or indirectly lead to the occurrence and development of CHF [4]. Heart failure brings a heavy burden to the society and the family; therefore, it is very indispensable for the prevention and treatment of CHF [5].

Nowadays, metoprolol succinate is often employed in the clinical treatment of CHF. Metoprolol succinate is a selective β1-receptor blocker, which attaches importance to the control of hypertension and CHD, however, the clinical efficacy of metoprolol succinate alone when treating CHF needs to be enhanced [6]. In recent years, with the advent of drugs such as angiotensin receptor/enkephalin inhibitor (ARNI), there has been a great breakthrough in the treatment of CHF. As a kind of ARNI drugs, Entresto (Sacubitril Valsartan Sodium Tablets) are mainly composed of sacubitril and valsartan at 1:1. They can block angiotensin II receptor and inhibit enkephalin through LBQ657, the metabolite of sacubitril valsartan, which have beneficial effects on relaxing blood vessels, preventing and reversing cardiovascular remodeling and promoting urinary sodium excretion [7]. Meanwhile, previous studies have indicated that Entresto may also be effective in the fight against myocardial fibrosis, antisynthetic nervous system activity, inhibition of antidiuretic hormone release, improvement of myocardial relaxation and vagus nerve tension, and antimyocardial hypertrophy [8, 9]. For patients with CHF, studies have indicated that ACEI and ARB play a certain part in improving symptoms and reducing hospitalization rate [10]. Most of the treatment for CHF is symptomatic treatment [11]. In 2012, a phase II clinical trial PARAMOUNTHF study of Entresto was published. It was found that Entresto reduced BNP in patients with CHF at 12 weeks of treatment compared with valsartan in the control group and indicated a decrease in left atrial volume (LAV) and an improvement in cardiac function classification at 36 weeks of treatment compared with the control group [12]. Considering that natriuretic peptide is a strong predictor of poor cardiovascular prognosis in patients with CHF, the results of this study also lead researchers to expect that Entresto can benefit patients with heart failure [12]. However, as a new drug, the dosage and efficacy of Entresto in clinical application of various types of CHF are not clear, and the clinical efficacy of Entresto combined with metoprolol succinate when treating CHF is worthy of further exploration. Therefore, this study conducted an observational study on patients with CHF who were treated with Entresto and metoprolol succinate sustained-release tablets combined with Entresto in our hospital to evaluate the efficacy of this drug in clinic, in order to assist the better clinical application of Entresto to optimize the treatment of patients with CHF.

2. Patients and Methods

2.1. Demographic Information. A total of 120 patients with CHF treated from April 2018 to April 2021 were enrolled in our hospital. The patients were arbitrarily assigned into control group and study group. In the control group, the age was 36–77 years old, and the course of disease was 2–14 years, while in the study group, the age was 36–78 years old, and the course of disease was 2–13 years. There exhibited no statistical significance in the general data (see Table 1). This study was permitted by the Medical Ethics Association of our hospital, and written informed consent was obtained from all patients.

Inclusion criteria: the diagnostic criteria of heart failure: according to the 2018 Chinese guidelines for the diagnosis and treatment of heart failure [13], the classification and diagnostic criteria of chronic heart failure are as follows: (1) heart failure with decreased ejection fraction- (HFREF-) combined with the patient’s history, symptoms, and signs of heart failure; if the patient’s LVEF is less than 40%, it is diagnosed as HFREF. (2) Heart failure with preserved ejection fraction- (HFPEF-): if the patient has a history, symptoms, and signs of heart failure; if the patient’s LVEF ≥ 50% and natriuretic peptide are elevated, at least one of the following items is satisfied: (i) left ventricular hypertrophy and/or left atrial enlargement and (ii) cardiac diastolic dysfunction; excluding the patient’s symptoms caused by nonheart disease, the patient is diagnosed as HFPEF.

Exclusion criteria: (1) history of vascular edema; (2) severe stenosis of bilateral renal arteries; (3) symptomatic hypotension (systolic blood pressure < 95 mmHg); (4) severe liver damage (Child Pugh grade C); (5) biliary cirrhosis; (6) cholestasis; (7) pregnant and lactating women; (8) serum potassium > 5.4 mmol/L; (9) severe renal insufficiency (serum creatinine > 221 μmol/L (2.5 mg/dl) or eGFR < 30 mL/min/1.73 m²); (10) malignant tumor; (11) history of allergy to ARB, ACEI, or ARNI drugs or similar chemical drugs; and (12) cardiac valvular disease.

2.2. Treatment Methods. The control group was given metoprolol succinate sustained-release tablets (manufacturer: AstraZeneca Pharmaceutical Co., Ltd; Chinese medicine standard: J20150044) treatment, 23.75–47.50 mg can be added according to the recovery of the disease dose, but the single dose should not exceed 190 mg once per day. The study group was treated with Sacubitril Valsartan Sodium Tablets (manufacturer: Beijing Novartis Pharmaceutical Co., Ltd.; Chinese Medicine Standard: J20190001) on the basis of the control group, 50–100 mg/twice per day. Both groups were treated continuously for 14 days.

2.3. Observation Index

2.3.1. General Information. Access to patient-related case data, record all enrolled patients’ age, sex, course of disease, hypertension, coronary heart disease, diabetes, atrial fibrillation, and other general data.

2.3.2. Clinical Efficacy Evaluation. The clinical effects were compared. The criteria are as follows: significant effect:
dyspnea, fatigue, lung rale, cough, jugular vein anger, and other symptoms basically disappeared, arrhythmia decreased by more than 90%, cardiac function improved by 2 or more grades; effective: dyspnea, fatigue, lung rale, cough, jugular vein anger, and other symptoms improved, arrhythmia grades; ineffective: dyspnea, fatigue, lung rale, cough, jugular vein anger, and other symptoms do not change or aggravate. Total effective rate = (number of effective cases + number of effective cases)/total number of cases × 100%.

2.3.3. Cardiac Function Index. The cardiac function indexes left ventricular ejection fraction (LVEF), left ventricular end-systolic diameter (LVESD), and left ventricular end-diastolic diameter (LVEDD) were compared before and after treatment. Siemens ACUSONX150 color Doppler ultrasound system was employed for detection.

2.3.4. Vascular Endothelial Function Index. The indexes of vascular endothelial function calcitonin gene-related peptide (CGRP), nitric oxide (NO), and endothelin (ET) were compared before and after treatment. CGRP and ET were detected by enzyme-linked immunosorbent assay (ELISA). Griess’s reagent (Griess) was employed to detect NO.

2.3.5. Oxidative Stress Index. The indexes of oxidative stress, containing glutathione peroxidase (GSH-Px), superoxide dismutase (SOD), and malondialdehyde (MDA), were compared before and after treatment. GSH-Px was detected by colorimetry, and SOD was detected by ELISA, then, MDA was detected by thiobarbituric acid method.

2.3.6. Blood Coagulation Index. The coagulation indexes were compared before and after treatment, APTT: activated partial prothrombin time, PT: prothrombin time, and FIB: fibrinogen. The blood samples of patients were collected, and APTT, PT, and FIB were detected by automatic coagulation analyzer.

2.3.7. Incidence of Adverse Reactions. Statistics on the incidence of adverse reactions between the two groups.

2.4. Statistical Analysis. SPSS 22.00 was adopted to process the relevant data in this study and complete the relevant statistical analysis. Meanwhile, the quantitative data should be in accordance with the normal distribution, represented by the mean ± standard deviation x ± s. The independent samples used between different groups were mainly completed by t-test. Paired t-test was employed to compare the data before and after treatment. χ² test or corrected χ² test was used to complete the test of qualitative data, and the percentage (%) was employed to express the results of qualitative data. P < 0.05 indicated that there exhibited statistical difference.

3. Results

3.1. Comparison of Demographic Data. First of all, we compared the general data, there exhibited no significant difference in age, sex, course of disease, hypertension, coronary heart disease, diabetes, atrial fibrillation, and other general data (P > 0.05). All the results are shown in Table 1.

3.2. Comparison of Clinical Efficacy. Second, we compared the clinical efficacy, and the effective rate of the study group (98.33%) was higher compared to the control group (90.00%) (P < 0.05). All the results are indicated in Figure 1.

3.3. Comparison of Cardiac Function Indexes. Next, we compared the cardiac function indexes. There exhibited no significant difference before treatment, however, the LVEF increased, LVESD and LVEDD decreased, and the LVESD and LVEDD of the study group were lower compared to the control group after treatment, while LVEF was higher compared to the control group (P < 0.05). All the results are shown in Table 2.

3.4. Comparison of Vascular Endothelial Function Indexes. Then, we compared the indexes of vascular endothelial function, there exhibited no significant difference before treatment, of note, after treatment, the levels of CGRP and ET increased and the levels of NO decreased, and the level of NO in the study group was lower, while the levels of CGRP and ET in the study group were higher (P < 0.05). All the results are indicated in Table 3.

3.5. Comparison of Oxidative Stress Indexes. Next, we compared the oxidative stress indexes, there exhibited no significant difference before treatment, however, the levels of GSH-Px and SOD increased and the levels of MDA decreased, and the level of MDA in the study group was lower after treatment, while the levels of GSH-Px and SOD

| Group | C group (n = 60) | R group (n = 60) | t/χ² | P |
|-------|----------------|----------------|------|---|
| Age (years) | 55.81 ± 3.53 | 55.83 ± 3.52 | 0.031 | 0.975 |
| Gender (male/female) | 35/25 | 31/29 | 0.538 | 0.462 |
| Course of disease (year) | 8.38 ± 2.11 | 8.39 ± 2.44 | 0.024 | 0.980 |
| Diabetic history | 24 (40.00) | 26 (43.33) | | |
| Coronary artery disease | 17 (28.33) | 15 (25.00) | 0.315 | 0.957 |
| Diabetes | 12 (20.00) | 11 (18.33) | | |
| Atrial fibrillation | 7 (11.67) | 8 (13.34) | | |
in the study group were higher \((P < 0.05)\). All the results are indicated in Table 4.

3.6. Comparison of Coagulation Function Indexes. Finally, we compared the indexes of blood coagulation function, there exhibited no significant difference before treatment, but after treatment. The levels of APTT, PT, and FIB decreased, and the levels of APTT, PT, and FIB in the study group were lower \((P < 0.05)\). All the data results are indicated in Table 5.

3.7. Comparison of the Incidence of Side Effects between the Two Groups. Finally, we compared the incidence of adverse reactions. The incidence of side effects in the control group is 11.67%. The incidence of side effects in the study group is 3.33%, the study group was lower than the control group \((P < 0.05)\). All the data results are indicated in Figure 2.

4. Discussion

CHF is a common cardiovascular disease in clinic, which often occurs in the middle-aged and elderly stage, with the characteristics of long course of disease, complex etiology, and various complications [1]. CHF has adverse effects on the health of tens of millions of people around the world and is regarded as the fastest growing cardiovascular disease with high incidence and high cost of treatment [2]. The relevant study implicates that the onset and development of CHF are closely related to various factors, and the key mechanism lies in the excessive activation of neuroendocrine system and cytokines, leading to gradual myocardial remodeling and continuous progress of CHF [14]. In the actual classification of CHF, the key to death in these patients depends on the relevant indicators of the left
ventricle (LV) of CHF [15]. Patients with CHF can be treated with antiplatelet drugs, statins, diuretics, cardiotonic agents, and so on, among which metoprolol succinate is a commonly used drug in clinic [16]. Related research results indicate that metoprolol succinate can reduce sympathetic excitability, reduce myocardial oxygen consumption, and dilate blood vessels [17]. Metoprolol succinate can reduce blood pressure and heart rate. However, metoprolol succinate alone is not effective in the treatment of CHF [16].

The advent of Entresto (Sacubitril Valsartan Sodium Tablets) plays a potential part in the treatment and prognosis of CHF [18]. Through the persistence of many parties, the listing of Entresto has opened a new way to the treatment of CHF. The components of Entresto include equal proportion of sacubitril and valsartan. From acute to chronic phase, a number of important clinical trials have been published, containing the PARADIGM-HF study, the TRANSITION study, and the PIONEER-HF study [19]. Based on these findings, the first-line treatment of patients with ejection fraction retention heart failure (HFPEF) is determined to be Entresto, which was included in “European and American Heart failure guidelines,” “2018 Chinese Heart failure guidelines,” and “2019 European Heart failure Association expert consensus” [20]. In addition, the highest blood concentration can be achieved at 1.5-4.5 h after oral administration, the blood drug value can be maintained in the patient’s body after 3 days, and the bioavailability is excellent [21].

Studies have confirmed that Entresto can also reduce enkephalinase activity [22]. Combination with metoprolol succinate in the treatment of CHF can give full play to their vasodilation effect, directly relax arteriole smooth muscle and reduce cardiac load, helping patients improve cardiac function [23]. Entresto is a new type of double-effect

### Table 4: Comparison of oxidative stress indexes between the two groups (x ± s).

| Group | N  | Before treatment | After treatment | Before treatment | After treatment | Before treatment | After treatment |
|-------|----|------------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| C     | 60 | 135.89 ± 9.55    | 235.85 ± 8.45   | 71.92 ± 4.92    | 80.87 ± 5.93    | 27.98 ± 4.56    | 21.87 ± 3.64    |
| R     | 60 | 135.94 ± 9.67    | 365.61 ± 8.38   | 71.93 ± 4.39    | 95.86 ± 4.97    | 27.94 ± 4.49    | 13.19 ± 1.92    |
| t     | 0.028 | 84.458    | 0.011       | 15.006        | 0.048         | 16.337        |
| P     | 0.977 | 0.000       | 0.000       | 0.000         | 0.961         | 0.000         |

Note: the control group before and after treatment, aP < 0.05; the study group before and after treatment, bP < 0.05.

### Table 5: Comparison of blood coagulation function indexes between the two groups (x ± s).

| Group | N  | Before treatment | After treatment | Before treatment | After treatment | Before treatment | After treatment |
|-------|----|------------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| C     | 60 | 42.86 ± 3.31     | 37.85 ± 3.42    | 15.73 ± 2.83    | 12.74 ± 1.74    | 4.52 ± 1.22     | 2.79 ± 0.55     |
| R     | 60 | 42.84 ± 3.13     | 32.16 ± 3.11    | 15.48 ± 2.35    | 10.85 ± 1.67    | 4.59 ± 1.34     | 2.01 ± 0.33     |
| t     | 0.034 | 9.534       | 0.544       | 6.070          | 0.299          | 9.419          |
| P     | 0.972 | 0.000       | 0.586       | 0.000          | 0.765          | 0.000          |

Note: the control group before and after treatment, aP < 0.05; the study group before and after treatment, bP < 0.05.

Figure 2: Comparison of incidence of adverse reactions between two groups.
compound preparation, which can regulate the function of nervous system by reducing the secretion of aldosterone. In addition, Entresto can also reduce the accumulation of macrophages, maintain the dynamic balance of extracellular matrix, and then regulate the physiological activity of cells [22, 23]. Therefore, Entresto can make up for the deficiency of metoprolol succinate in regulating nervous system function and cell physiological activity, enhance the recovery of patients, and strengthen the therapeutic effect [23]. In line with this, our current results demonstrated that the total effective rate of the study group was higher, and after treatment, LVEF in the study group was higher. In the late 1990s, the doctors have realized that the basic mechanism of CHF is myocardial remodeling, which is the pathophysiological basis for the continuous progress of CHF [24]. When the cardiac function is damaged, the extracellular matrix and cardiomyocytes will have certain changes, and the transformation of cardiomyocytes includes cardiomyocyte apoptosis and necrosis [24]. Moreover, when the tension of the cardiovascular system is too high, the newly synthesized substances cannot divide into normal cardiomyocytes and cannot enter the normal cell cycle. If the differentiation of the cell is hindered, it may lead to compensatory growth or hypertrophy [24, 25]. According to relevant clinical trials, when the cardiac cavity is enlarged, LVEF is an independent risk factor for predicting the prognosis of CHF, which is inversely proportional to the mortality of CHF [25]. Therefore, our results suggest that Entresto combined with metoprol succinate is effective when treating CHF and can validly enhance cardiac function.

Vascular endothelium is an important endocrine organ, which can regulate vascular tension and hematopoietic function, but when vascular endothelial function is disordered, it can accelerate the differentiation and apoptosis of endothelial cells, reduce the synthesis of NO, and then reduce its regulation of vascular tension [26]. Entresto can enhance vascular wall function by blocking local tissue RAAS activation, which can make up for the deficiency of metoprol succinate and help patients improve vascular endothelial function [26]. The results of this study indicated that after treatment, CGRP and NO were higher, ET was lower, GSH-Px and SOD were higher, and MDA was lower compared to the control group. It is suggested that Entresto combined with metoprol succinate could effectively strengthen vascular endothelial function and reduce oxidative stress in patients with CHF. Furthermore, Entresto can accelerate the degradation rate of enkephalin, then increase the level of NP, and promote the excretion of urine and sodium, so as to prevent cardiomyocyte fibrosis and help patients reduce myocardial injury [27]. Metoprol succinate cannot only reduce endogenous sympathetic activity but also reduce myocardial oxygen consumption, protecting cardiomyocytes [27]. Therefore, the treatment of CHF with Entresto combined with metoprol can reduce the stress injury and reduce the oxidative stress reaction [27]. In terms of blood coagulation function, plasma prothrombin time mainly reflects the function of exogenous coagulation system, and its prolongation is mainly seen in congenital decrease of coagulation factor and fibrinogen deficiency [28]; activated partial thrombin time is mainly the examination index of endogenous coagulation factor deficiency, and its prolongation is common in hemophilia hepatopathy, DIC, and so on [29]; prolonged plasma thrombin time is common in patients with hypofibrinogenemia and abnormal fibrinemia [30]. In terms of the results of this study, the blood coagulation indexes were compared; the levels of APTT, PT, and FIB decreased; and the levels of APTT, PT, and FIB in the study group were lower compared to the control group after treatment. Our results suggest that Entresto combined with metoprol succinate can effectively enhance the blood coagulation index, reduce blood viscosity, and further promote the clinical prognosis of patients.

Collectively, clinical practice demonstrated that LVESD and LVEED decreased and LVEF increased after treatment with Entresto combined with metoprol in CHF patients, which can effectively facilitate cardiac function and vascular endothelial function, reduce oxidative stress reaction, and improve blood coagulation indexes, suggesting that Entresto combined with metoprol can improve ventricular remodeling with good safety.

**Data Availability**

No data were used to support this study.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**References**

[1] W. Hongjuan and T. Qile, “Effects of sarcophroxtan combined with metoprol on cardiac function, vascular endothelial function and neuroendocrine factors in elderly patients with chronic heart failure,” Chinese Journal of Gerontology, vol. 41, no. 23, pp. 5183–5187, 2021.

[2] Ohio State University Wexner medical center, “Scientists ID new metabolic target to prevent, treat heart failure at earliest stage,” NewsRx Health & Science, vol. 64, no. 34, pp. 134–139, 2019.

[3] L. Wei, Z. Cui, W. Guoyu et al., “Effects of different nutritional status on IGF-1 and IL-17 levels in elderly patients with chronic congestive heart failure,” Chinese Journal of Gerontology, vol. 41, no. 21, pp. 4608–4610, 2021.

[4] S. P. Murphy, N. E. Ibrahim, and J. L. Januzzi Jr., “Heart Failure With Reduced Ejection Fraction: A Review,” JAMA, vol. 324, no. 5, pp. 488–504, 2020.

[5] S. Jie and C. Xin, “Evaluation of the efficacy of salkuridine and valsartan in patients with chronic heart failure in different course of disease,” Journal of Clinical Cardiovascular Diseases, vol. 37, no. 10, pp. 942–946, 2021.

[6] V. Muthiah and L. Januzzi James Jr., “Preventing and treating heart failure with sodium-glucose co-transporter 2 inhibitors,” The American Journal of Medicine, vol. 132, no. 10, pp. 594–598, 2019.

[7] S. Lee, J. Oh, H. Kim et al., “Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end-stage of renal disease,” ESC Heart Fail, vol. 7, no. 3, pp. 1125–1129, 2020.
[8] W. Wang, Q. L. Li, Q. Ma et al., “Effect of moxibustion combined with benazepril on expression of IL-18 and phosphorylated protein kinase B in myocardial tissue of rats with chronic heart failure,” *Zhen Ci Yan Jiu*, vol. 46, no. 11, pp. 935–941, 2021.

[9] S. Nichols, G. McGregor, J. Breckon, and L. Ingle, “Current Insights into Exercise-based Cardiac Rehabilitation in Patients with Coronary Heart Disease and Chronic Heart Failure,” *International Journal of Sports Medicine*, vol. 42, no. 1, pp. 19–26, 2021.

[10] Y. D. Yu, Y. P. Xiu, Y. F. Li, and Y. T. Xue, “To explore the mechanism and equivalent molecular group of fuxin mixture in treating heart failure based on network pharmacology,” *Evidence-based Complementary and Alternative Medicine*, vol. 2020, no. 876, p. 10, 2020.

[11] D. L. Mann, M. M. Givertz, J. M. Vader et al., “LIFE Investigators. Effect of Treatment With Sacubitril/Valsartan in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial,” *JAMA cardiology*, vol. 7, no. 1, pp. 17–25, 2022.

[12] J. Adler, F. Gerhardt, M. Wissmüller, C. Adler, S. Baldus, and S. Rosenkranz, “Pulmonary hypertension associated with left-sided heart failure,” *Current Opinion in Cardiology*, vol. 35, no. 6, pp. 610–619, 2020.

[13] A. González, E. B. Schelbert, J. Díez, and J. Butler, “Myocardial interstitial fibrosis in heart failure: biological and translational perspectives,” *Journal of the American College of Cardiology*, vol. 71, no. 15, pp. 1696–1706, 2018.

[14] F. Lei, M. Zhao, H. Wang, C. Pan, and X. Shi, “Discussion on the mechanism of action of high-frequency drugs for treating heart failure based on network pharmacology,” *Journal of Clinical and Nursing Research*, vol. 5, no. 3, pp. 56–58, 2021.

[15] J. E. Emmens, J. M. Ter Maaten, F. P. Brouwers et al., “Proenkophile and the risk of new-onset heart failure: data from prevention of renal and vascular end-stage disease,” *Clinical cardiology*, vol. 44, no. 12, pp. 1662–1672, 2021.

[16] Cardiora Pty Ltd, “Patent issued for method of treating HFPEF by administering milrinone (USPTO 10, 493, 067),” *Chemicals & Chemistry*, vol. 17, no. 77, pp. 165–169, 2019.

[17] D. Scrutinio, F. Conserva, P. Guida, and A. Passantino, “Long-term prognostic potential of microRNA-150-5p in optimally treated heart failure patients with reduced ejection fraction. A pilot study,” *Minerva Cardioangiologica*, vol. 153, no. 44, pp. 165–169, 2020.

[18] V. Muthiah and J. L. Januzzi, “Preventing and treating heart failure with sodium-glucose co-transporter 2 inhibitors,” *The American Journal of Cardiology*, vol. 124, no. S1, pp. S20–S27, 2019.

[19] C. Chi-Ryang, Z. Yuxin, and L. Guoshuai, “Clinical efficacy and safety of Tongxinluo capsule combined with shakubatrixinartan in the treatment of senile chronic heart failure,” *Chinese Journal of traditional Chinese Medicine*, vol. 23, no. 55, pp. 942–946, 2021.

[20] J. K. D. Jacobsson, C. Reitan, R. Borgquist, J. Carlson, and P. P. Platonov, “P5683Incremental hazard associated with the degree of advanced intaratral block in cardiac resynchronization therapy treated heart failure patients,” *European Heart Journal*, vol. 40, Supplement 1, pp. 49–53, 2019.

[21] M. Ieda, “Key regulators of cardiovascular differentiation and regeneration: harnessing the potential of direct reprogramming to treat heart failure,” *Journal of Cardiac Failure*, vol. 26, no. 1, pp. 843–849, 2019.

[22] B. H. Belnap, A. Anderson, K. Z. Abebe et al., “Blended collaborative care to treat heart failure and comorbid depression: rationale and study design of the hopeful heart trial,” *Psychosomatic Medicine*, vol. 81, no. 6, pp. 495–505, 2019.

[23] “Procyrion raises $30 million series D to support clinical trials of its Aortix™ percutaneous blood pump for treating heart failure patients; device’s unique placement in the descending aorta allows it to rest the heart while improving blood flow to the kidneys,” *M2 Presswire*, vol. 585, no. 55, pp. 1677–1679, 2019.

[24] I. R. Mordi, B. T. Santema, M. Kloosterman et al., “Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation,” *Clinical Research in Cardiology*, vol. 108, no. 7, pp. 797–805, 2019.

[25] M. Pinilla-Vera, V. S. Hahn, and D. A. Kass, “Leveraging signaling pathways to treat heart failure with reduced ejection fraction,” *Circulation Research*, vol. 124, no. 11, pp. 1618–1632, 2019.

[26] Z. Jinyan, C. Shaonan, and C. Yuejuan, “Observation on the efficacy of Shakubaqu valsartan sodium in the treatment of senile hypertensive chronic heart failure,” *Chinese Journal of Geriatric Cardiovascular and Cerebrovascular Diseases*, vol. 23, no. 12, pp. 1268–1271, 2021.

[27] “Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure,” *British Journal of Pharmacology and Chemotherapy*, vol. 175, no. 2, pp. 223–231, 2018.

[28] Y. Hernaningsih and J. S. Akueling, “The effects of hemolysis on plasma prothrombin time and activated partial thromboplastin time tests using photo-optical method,” *Medicine (Baltimore)*, vol. 96, no. 38, article e7976, 2017.

[29] X. Xu and Q. Liang, “Dabigatran monitoring was influenced by thrombin time reagent with different thrombin concentrations,” *Clinical and Applied Thrombosis/Hemostasis*, vol. 25, p. 107602961986713, 2019.

[30] T. E. Thayer, R. T. Levinson, E. Farber-Eger et al., “Abstract 14372; identification of genetic variants associated with progression of left ventricular diastolic dysfunction: a screening analysis for repurposing existing medications to treat HFPEF,” *Circulation*, vol. 15, no. 67, pp. 16–19, 2018.